NAV

Sulfachlorpyridazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sulfachlorpyridazine
DrugBank Accession Number
DB11461
Background

A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.

Type
Small Molecule
Groups
Vet approved
Structure
3D
Similar Structures
Weight
Average: 284.72
Monoisotopic: 284.0134744
Chemical Formula
C10H9ClN4O2S
Synonyms
  • 4-Amino-N-(6-chloro-3-pyridazinyl)benzenesulfonamide
  • 4-amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide
  • N1-(6-Chloro-3-pyridazinyl)sulfanilamide
  • SCP
  • Sulfachloropyridazine
  • Sulfachlorpyridazine
  • Sulfachlorpyridazinum
  • Sulfacloropiridazina
  • Sulphachlorpyridazine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Sulfachlorpyridazine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfachlorpyridazine.
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfachlorpyridazine.
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfachlorpyridazine.
BenzylpenicillinSulfachlorpyridazine may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Sodium sulfachlorpyridazine monohydrateKPM50228FR1392129-96-2PCDSLLFCMAPONC-UHFFFAOYSA-N
Sulfachlorpyridazine sodiumN1LMA4960O23282-55-5ODWMXYHUKDMPTR-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Aniline and substituted anilines / Pyridazines and derivatives / Organosulfonamides / Imidolactams / Aryl chlorides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Primary amines
show 4 more
Substituents
Amine / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenesulfonyl group / Heteroaromatic compound
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, organochlorine compound, pyridazines (CHEBI:59057)
Affected organisms
Not Available

Chemical Identifiers

UNII
P78D9P90C0
CAS number
80-32-0
InChI Key
XOXHILFPRYWFOD-UHFFFAOYSA-N
InChI
InChI=1S/C10H9ClN4O2S/c11-9-5-6-10(14-13-9)15-18(16,17)8-3-1-7(12)2-4-8/h1-6H,12H2,(H,14,15)
IUPAC Name
4-amino-N-(6-chloropyridazin-3-yl)benzene-1-sulfonamide
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC1=NN=C(Cl)C=C1

References

General References
  1. Marino EL, Tabernero JM, Macias JG, Dominguez-Gil A, de Castro S: [Pharmacokinetics of sulfachlorpyridazine]. Arch Farmacol Toxicol. 1979 Apr;5(1):57-71. [Article]
  2. STRAUSS B, FLEMING A: SULFACHLORPYRIDAZINE IN CHRONIC URINARY-TRACT INFECTIONS. West Med Med J West. 1964 Mar;5:81-4. [Article]
  3. Rothenberg NA, Tindall EE: Sulfachlorpyridazine for treatment of infectious canine tracheobronchitis. Vet Med Small Anim Clin. 1968 Nov;63(11):1075-6. [Article]
  4. SENECA H, LATTIMER JK, ZINSSER HH: CHEMOTHERAPY OF URINARY-TRACT INFECTIONS WITH SULFACHLORPYRIDAZINE (SONILYN). J Am Geriatr Soc. 1963 Aug;11:815-22. [Article]
  5. TRAFTON HM, LIND HE: CLINICAL EVALUATION OF SULFACHLORPYRIDAZINE IN URINARY TRACT INFECTIONS. J Urol. 1963 Sep;90:308-16. [Article]
  6. Alavi FK, Rolf LL, Clarke CR: The pharmacokinetics of sulfachlorpyridazine in channel catfish, Ictalurus punctatus. J Vet Pharmacol Ther. 1993 Jun;16(2):232-6. [Article]
  7. Linster N, Hinz KH: [In vivo effectiveness of the sulfonamide sulfachlorpyridazine (SCP) and of the combination of sulfachlorpyridazine and trimethoprim (SCP + TMP) against Haemophilus paragallinarum]. Dtsch Tierarztl Wochenschr. 1983 May 6;90(5):170-3. [Article]
  8. Davis WT, Reynolds WA, Maplesden DC: Comparison of ampicillin and sulfachlorpyridazine in treatment of colibacillosis in swine. Vet Med Small Anim Clin. 1973 Aug;68(8):847-8 passim. [Article]
  9. GOLDHAMMER H: [Sulfachlorpyridazine in the treatment of coli infections of the urinary and biliary tracts]. Arzneimittelforschung. 1961 Feb;11:131-2. [Article]
  10. Spinks CA, Schut CG, Wyatt GM, Morgan MR: Development of an ELISA for sulfachlorpyridazine and investigation of matrix effects from different sample extraction procedures. Food Addit Contam. 2001 Jan;18(1):11-8. [Article]
  11. Harle DG, Baldo BA, Wells JV: Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol. 1988 Dec;25(12):1347-54. [Article]
KEGG Drug
D05948
ChemSpider
6382
BindingDB
90673
RxNav
2476008
ChEBI
59057
ChEMBL
CHEMBL1443577
ZINC
ZINC000000049140
Wikipedia
Sulfachlorpyridazine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionOral
Powder, for solutionOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.133 mg/mLALOGPS
logP0.97ALOGPS
logP0.85Chemaxon
logS-3.3ALOGPS
pKa (Strongest Acidic)6.6Chemaxon
pKa (Strongest Basic)2.02Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area97.97 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity71.48 m3·mol-1Chemaxon
Polarizability25.94 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-1900000000-d2bc1c887f6f99ed0f74
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0390000000-f4a424d90c5a013801aa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-ab650ec0859bd7decedc
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-0690000000-0c668c1b4670fafb1365
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0190000000-33cbb5df33988b425e76
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00lu-9520000000-b4bcf97f08f6630a81c3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052g-5900000000-2809f4275e386d872c3b
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-163.38464
predicted
DeepCCS 1.0 (2019)
[M+H]+165.74265
predicted
DeepCCS 1.0 (2019)
[M+Na]+171.8358
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:56 / Updated at February 21, 2021 18:53